NEW YORK, Sept. 02, 2023 (GLOBE NEWSWIRE) --
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements that: (i) the design of SYFOVRE's clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections; (ii) as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors; and (iii) therefore, the Company's statements about its business, operations, and prospects lacked a reasonable basis.
If you are an APLS investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
RTX Corp. (NYSE:RTX)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose that: (i) GTF engines had been affected from at least 2015-2020 by a quality control issue; (ii) this ...
RTX), Live Nation Entertainment, Inc. (NYSE: LYV), and KeyCorp (NYSE: KEY)>Full story available on Benzinga.com